You are here: Home 
Categories Prostate Cancer
Categories Prostate Cancer First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients - Abstract
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients - Abstract
Published on 03 September 2012
BACKGROUND:We developed a novel non-emulsion depot-forming vaccine platform called DepoVaxTM with the capacity to significantly enhance peptide cancer antigen immunogenicity.
To read more, a FREE Urotoday registration is required. Click here to register or login above.To read UIJ content, a separate subscription is required.
Tags:
